July 08, 2026 —
A new study published in Nature Biotechnology describes a gene therapy strategy that uses the brain’s glymphatic transport system to distribute engineered viral vectors throughout the brain. The approach addresses two major challenges in neurological gene therapy: reaching targets behind the blood-brain barrier and limiting unwanted exposure elsewhere in the body.
The platform combines specially engineered adeno-associated virus 5, or AAV5, vectors with a delivery strategy that harnesses the brain’s natural cerebrospinal fluid transport pathways. Together, these innovations enabled researchers to deliver therapeutic genes broadly across brain tissue while preferentially targeting human glial cells and minimizing exposure to other cell types and peripheral organs.
The study was led by Steve Goldman, MD, PhD, co-director of the University of Rochester Medicine Center for Translational Neuromedicine. Goldman’s work has long focused on glial cells, the support cells of the nervous system that help maintain brain function, produce myelin, and regulate neuronal health. Increasing evidence suggests that glial dysfunction contributes to neurological diseases including Huntington’s disease, multiple sclerosis, and inherited white matter disorders.
To develop glia-targeted vectors, the researchers engineered a library of modified AAV5 capsids. Each vector contained small changes to the viral capsid, which determines cell tropism. The team screened these vectors in mice whose brains had been transplanted with human glial progenitor cells, allowing selection under biologically relevant in vivo conditions.
Using a genetic tracking system, the researchers identified viral variants that most effectively infected human glial cells in the living brain. The resulting vectors preferentially targeted human glial progenitor cells and their descendants, including astrocytes and oligodendrocytes, while showing limited infection of peripheral tissues.
The delivery strategy relied on the glymphatic system, a network of fluid-filled pathways that circulates cerebrospinal fluid through brain tissue and helps clear metabolic waste. The researchers delivered the engineered AAVs into the cisterna magna, a cerebrospinal fluid-filled compartment at the base of the brain, while using hypertonic treatment to enhance fluid uptake into the glymphatic network.
This approach enabled the vectors to spread broadly through the brain while largely bypassing the blood-brain barrier. Because the vectors were concentrated within the brain, the strategy also reduced exposure to peripheral organs such as the liver, a common safety concern in systemic AAV gene therapy.
The platform may be particularly relevant for disorders involving glial dysfunction or white matter pathology. Potential applications include pediatric lysosomal storage diseases, inherited leukodystrophies, multiple sclerosis, age-related white matter loss, Huntington’s disease, and other neurodegenerative disorders in which glial cells contribute to disease progression.
The study also establishes a framework for discovering and optimizing vectors tailored to specific cell types. Goldman’s team is exploring the use of artificial intelligence to design viral capsids with desired targeting characteristics, potentially accelerating the development of next-generation CNS gene therapies.
While the findings remain preclinical, the work highlights a promising strategy for neurological gene therapy: combining targeted AAV capsid engineering with delivery through the brain’s own fluid transport system. If successfully translated, glymphatic AAV delivery could help enable broader and more selective treatment of diseases that require widespread gene delivery across the brain.
